Cancer Immunotherapies: Are They as Effective in the Elderly?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cancer Immunotherapies: Are They as Effective in the Elderly?

Published:2017-07-13 Issue:8 Volume:34 Page:567-581
ISSN:1170-229X
Container-title:Drugs & Aging
language:en
Short-container-title:Drugs Aging

Author:

Poropatich Kate,Fontanarosa Joel,Samant Sandeep,Sosman Jeffrey A.,Zhang Bin

Funder

National Cancer Institute

Walter S. and Lucienne Driskill Immunotherapy Research fund

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Geriatrics and Gerontology

Link

http://link.springer.com/article/10.1007/s40266-017-0479-1/fulltext.html

Reference131 articles.

1. Beaver JA, Theoret MR, Mushti S, He K, Libeg M, Goldberg K, et al. FDA approval of nivolumab for the first-line treatment of patients with BRAFV600 wild-type unresectable or metastatic melanoma. Clin Cancer Res. 2017. doi: 10.1158/1078-0432.CCR-16-0714

2. Jotte RM, Socinski MA, Reck M, Papadimitrakopoulou V, West HJ, Mok T, et al. PS01.53: First-line atezolizumab plus chemotherapy in chemotherapy-naive patients with advanced NSCLC: a phase III clinical program: topic: medical oncology. J Thorac Oncol. 2016;11(11S):S302–3.

3. Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017;18(1):31–41.

4. Hazarika M, Chuk MK, Theoret MR, Mushti S, He K, Weis SL, et al. US FDA approval summary: nivolumab for treatment of unresectable or metastatic melanoma following progression on ipilimumab. Clin Cancer Res. 2017. doi: 10.1158/1078-0432.CCR-16-0712

5. Fulop T, Larbi A, Kotb R, de Angelis F, Pawelec G. Aging, immunity, and cancer. Discov Med. 2011;11(61):537–50.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of cellular senescence-associated genes as new biomarkers for predicting the prognosis and immunotherapy response of non-small cell lung cancer and construction of a prognostic model;Heliyon;2024-04

2. Efficacy and Safety of First-line Pembrolizumab Plus Platinum and Pemetrexed in Elderly Patients with Non-squamous Non-small-cell Lung Cancer;Internal Medicine;2024

3. Biomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma;Frontiers in Immunology;2023-12-22

4. A multicenter, open‐label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non‐small cell lung cancer;Thoracic Cancer;2023-09-17

5. Immune Checkpoint Inhibitors in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience from a Canadian Comprehensive Cancer Centre;Cancers;2023-08-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3